Hideko Isozaki

1.1k total citations
31 papers, 374 citations indexed

About

Hideko Isozaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hideko Isozaki has authored 31 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Hideko Isozaki's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). Hideko Isozaki is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). Hideko Isozaki collaborates with scholars based in Japan and United States. Hideko Isozaki's co-authors include Nagio Takigawa, Katsuyuki Kiura, Hiromichi Yamane, Nobuaki Ochi, Katsuyuki Hotta, Mitsune Tanimoto, Kadoaki Ohashi, Masayuki Yasugi, Eiki Ichihara and Toshiaki Sendo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Hideko Isozaki

24 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideko Isozaki Japan 9 209 207 198 54 43 31 374
James D. Peyton United States 10 175 0.8× 200 1.0× 145 0.7× 53 1.0× 28 0.7× 27 363
Marco Brugia Italy 12 117 0.6× 218 1.1× 128 0.6× 100 1.9× 32 0.7× 31 354
Paul Swanson United States 7 141 0.7× 212 1.0× 98 0.5× 37 0.7× 49 1.1× 9 334
Meiling Zhu China 14 199 1.0× 137 0.7× 156 0.8× 92 1.7× 40 0.9× 25 410
Eisuke Kurihara Japan 8 110 0.5× 148 0.7× 113 0.6× 48 0.9× 32 0.7× 12 271
Hailing Jin United States 10 183 0.9× 103 0.5× 118 0.6× 100 1.9× 32 0.7× 11 340
Elshad Hasanov United States 10 171 0.8× 105 0.5× 157 0.8× 109 2.0× 20 0.5× 36 323
A. Yovine United States 7 296 1.4× 184 0.9× 160 0.8× 100 1.9× 30 0.7× 13 447
Mark D. Kochenderfer United States 9 142 0.7× 231 1.1× 201 1.0× 75 1.4× 50 1.2× 14 366

Countries citing papers authored by Hideko Isozaki

Since Specialization
Citations

This map shows the geographic impact of Hideko Isozaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideko Isozaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideko Isozaki more than expected).

Fields of papers citing papers by Hideko Isozaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideko Isozaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideko Isozaki. The network helps show where Hideko Isozaki may publish in the future.

Co-authorship network of co-authors of Hideko Isozaki

This figure shows the co-authorship network connecting the top 25 collaborators of Hideko Isozaki. A scholar is included among the top collaborators of Hideko Isozaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideko Isozaki. Hideko Isozaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takamori, Shinkichi, Hideko Isozaki, Keisuke Shigeta, et al.. (2025). Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells. Cell Death Discovery. 11(1). 372–372.
2.
Takamori, Shinkichi, Atrayee Bhattacharya, Chie Kikutake, et al.. (2025). MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer. Signal Transduction and Targeted Therapy. 10(1). 389–389.
3.
Miyake, Noriko, Masami Takeyama, Hideko Isozaki, et al.. (2024). A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis. Experimental Cell Research. 442(2). 114266–114266. 1 indexed citations
4.
Haratake, Naoki, Hiroki Ozawa, Yoshihiro Morimoto, et al.. (2023). Abstract B089: MUC1-C is a common driver of acquired osimertinb resistance in NSCLC. Molecular Cancer Therapeutics. 22(12_Supplement). B089–B089. 2 indexed citations
5.
Haratake, Naoki, Hiroki Ozawa, Yoshihiro Morimoto, et al.. (2023). MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. Journal of Thoracic Oncology. 19(3). 434–450. 24 indexed citations
6.
Isozaki, Hideko, Ramin Sakhtemani, Lecia V. Sequist, et al.. (2023). Abstract 137: Epigenetic regulation of APOBEC3A mutagenesis and tumor evolution during targeted therapy in non-small cell lung cancer. Cancer Research. 83(7_Supplement). 137–137. 1 indexed citations
7.
Harada, Daijiro, Hideko Isozaki, Toshiyuki Kozuki, et al.. (2021). Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer. 12(5). 643–649. 8 indexed citations
8.
Piotrowska, Zofia, Hideko Isozaki, Jochen K. Lennerz, et al.. (2018). MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement. Journal of Thoracic Oncology. 13(10). S451–S451. 1 indexed citations
9.
Isozaki, Hideko, Eiki Ichihara, Nagio Takigawa, et al.. (2016). Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research. 76(6). 1506–1516. 109 indexed citations
10.
Ochi, Nobuaki, Hideko Isozaki, Masami Takeyama, et al.. (2016). Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Experimental Cell Research. 344(2). 194–200. 11 indexed citations
11.
Yamane, Hiromichi, Hideko Isozaki, Masami Takeyama, et al.. (2015). Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.. Europe PMC (PubMed Central). 5(4). 1553–7. 27 indexed citations
12.
Isozaki, Hideko, Masayuki Yasugi, Nagio Takigawa, et al.. (2014). A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. Japanese Journal of Clinical Oncology. 44(10). 963–968. 7 indexed citations
13.
Takigawa, Nagio, Nobuaki Ochi, Hiromichi Yamane, et al.. (2014). Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Design Development and Therapy. 8. 2401–2401. 6 indexed citations
14.
Isozaki, Hideko, Tomoaki Sato, Eiki Ichihara, et al.. (2012). Safety and Tolerability of Short Hydration Regimen for Cisplatin-based Chemotherapy in Patients with Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 38(3). 184–190.
15.
Iwagaki, Hiromi, Takahito Yagi, Naoto Urushihara, et al.. (1999). Modulatory effect of a serine protease inhibitor on surgical stress: its clinical implications.. PubMed. 53(5). 239–44. 4 indexed citations
16.
Isozaki, Hideko, Minoru Toyoda, Tomohiko Ishibashi, et al.. (1999). Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma.. PubMed. 45(24). 2458–63. 11 indexed citations
17.
Iwagaki, Hiromi, et al.. (1998). Is increased IL-1 beta mRNA expression in spleen of tumor-bearing mice relevant to cancer cachexia?. PubMed. 102(3). 241–9. 1 indexed citations
18.
Okajima, Kunio, et al.. (1996). [Measurement of the plasma transforming growth factor-beta 1 (TGF-beta 1) level in patients of gastric carcinoma--compared with the serum IAP level and the lymphocyte subsets (CD3, CD4, CD8)].. PubMed. 93(5). 303–11. 5 indexed citations
19.
Okajima, Kunio, et al.. (1989). [The indication for lymph node dissection around abdominal aorta in gastric cancer].. PubMed. 90(9). 1314–7. 1 indexed citations
20.
Nakajima, Teruyuki, et al.. (1987). [Role of extracellular matrix in the development of gastric carcinoma with special reference to the effects of collagen and glycosaminoglycans in cell culture].. PubMed. 88(12). 1755–1755. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James D. Peyton Breakdown of academic impact, for papers by Marco Brugia Breakdown of academic impact, for papers by Paul Swanson Breakdown of academic impact, for papers by Meiling Zhu Breakdown of academic impact, for papers by Eisuke Kurihara Breakdown of academic impact, for papers by Hailing Jin Breakdown of academic impact, for papers by Elshad Hasanov Breakdown of academic impact, for papers by A. Yovine Breakdown of academic impact, for papers by Mark D. Kochenderfer
Rankless by CCL
2026